** Shares of Biotech co AbCellera Biologics Inc ABCL.O up
1.5% to $5.2
** ABCL expands its existing multi-target antibody discovery
collaboration with Regeneron Pharmaceuticals REGN.O
** Under the expanded pact, ABCL to now discover therapeutic
antibodies for up to eight targets (from four targets
previously) selected by REGN
** Regeneron has the right to develop and commercialize
therapeutic antibodies resulting from the collaboration, which
has been in effect since March 2020
** AbCellera receives research payments and is eligible to
receive downstream clinical and regulatory milestone payments
and royalties on net sales of products
** Including session's gain, stock down ~49% YTD
(Reporting by Pratik Jain in Bengaluru)
((Pratik.Jain@thomsonreuters.com;))